| scholarly article | Q13442814 |
| P50 | author | Alessio Aghemo | Q42232991 |
| Pietro Lampertico | Q45354169 | ||
| P2093 | author name string | Massimo Colombo | |
| Mauro Viganò | |||
| P2860 | cites work | Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. | Q50569718 |
| Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. | Q50578652 | ||
| The long-term course of chronic hepatitis B. | Q53917500 | ||
| Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea | Q57215989 | ||
| Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C | Q58099679 | ||
| Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B | Q59306546 | ||
| Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study | Q61054098 | ||
| The natural history of chronic hepatitis B virus infection | Q64133519 | ||
| Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report | Q70313812 | ||
| Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B | Q71051138 | ||
| Lamivudine as initial treatment for chronic hepatitis B in the United States | Q73098368 | ||
| The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B | Q73700085 | ||
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group | Q27861083 | ||
| Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B | Q28212394 | ||
| Telbivudine versus lamivudine in patients with chronic hepatitis B | Q28261708 | ||
| Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial | Q28301659 | ||
| Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine | Q28372760 | ||
| Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 | ||
| Mechanism of action of interferon and ribavirin in treatment of hepatitis C | Q29619805 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group | Q30620502 | ||
| Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection | Q32086236 | ||
| Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy | Q33417353 | ||
| Chronic hepatitis B. | Q34002160 | ||
| Pegylation: a novel process for modifying pharmacokinetics | Q34340198 | ||
| Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. | Q34500537 | ||
| Lamivudine for patients with chronic hepatitis B and advanced liver disease | Q34551713 | ||
| Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. | Q34648995 | ||
| Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection | Q34775684 | ||
| Natural history and prognosis of hepatitis B. | Q35077631 | ||
| Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview | Q35621709 | ||
| A treatment algorithm for the management of chronic hepatitis B virus infection in the United States | Q35689607 | ||
| Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection | Q35903110 | ||
| Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B | Q35929532 | ||
| Management of antiviral resistance in patients with chronic hepatitis B. | Q35944417 | ||
| Pharmacokinetics of pegylated interferons: what is misleading? | Q36006851 | ||
| Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lesson from experimental models. | Q36091043 | ||
| Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update | Q36135493 | ||
| The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice | Q36346615 | ||
| Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment | Q36467970 | ||
| Mutations affecting the replication capacity of the hepatitis B virus | Q36515349 | ||
| Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. | Q36882276 | ||
| The changing epidemiology of hepatitis C virus infection in Europe | Q37006042 | ||
| Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors | Q37039155 | ||
| Hepatitis B: reflections on the current approach to antiviral therapy. | Q37096336 | ||
| EASL Clinical Practice Guidelines: management of chronic hepatitis B. | Q37340737 | ||
| Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides | Q37399490 | ||
| Worldwide mortality from cirrhosis: an update to 2002. | Q38463707 | ||
| Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study. | Q38924192 | ||
| Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. | Q40417514 | ||
| HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. | Q40620054 | ||
| Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. | Q40811419 | ||
| Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. | Q41604120 | ||
| A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. | Q42541246 | ||
| Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection | Q42983809 | ||
| Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. | Q42985188 | ||
| Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy | Q42985235 | ||
| Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial | Q42986993 | ||
| Telaprevir and peginterferon with or without ribavirin for chronic HCV infection | Q42987218 | ||
| Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study | Q42989003 | ||
| Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. | Q42993387 | ||
| Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia | Q42996604 | ||
| Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin | Q42999474 | ||
| Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy | Q42999651 | ||
| The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients | Q43000313 | ||
| A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). | Q43000679 | ||
| Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. | Q43040757 | ||
| Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial | Q43040967 | ||
| Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response | Q43041800 | ||
| Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. | Q43046858 | ||
| Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. | Q43507512 | ||
| Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy | Q43629454 | ||
| Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. | Q43662700 | ||
| Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. | Q43755030 | ||
| Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years | Q43914060 | ||
| Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion | Q43993343 | ||
| Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. | Q44005581 | ||
| Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. | Q44329201 | ||
| Durability of serologic response after lamivudine treatment of chronic hepatitis B. | Q44385915 | ||
| Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. | Q44385917 | ||
| Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. | Q44442885 | ||
| Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype | Q44520576 | ||
| Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase | Q44532948 | ||
| Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. | Q44671796 | ||
| Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment | Q44901526 | ||
| Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. | Q45023133 | ||
| Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. | Q45061899 | ||
| Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine | Q45070061 | ||
| Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. | Q45105367 | ||
| Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients | Q45227673 | ||
| HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. | Q45397583 | ||
| Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response | Q45399145 | ||
| Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. | Q45411398 | ||
| Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I | Q45752944 | ||
| Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. | Q46217486 | ||
| Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. | Q46408081 | ||
| Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b | Q46514441 | ||
| Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. | Q46575199 | ||
| Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. | Q46606214 | ||
| Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up | Q46629124 | ||
| Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. | Q46794204 | ||
| Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. | Q46827681 | ||
| Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. | Q46913808 | ||
| A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. | Q46981468 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P304 | page(s) | 484-509 | |
| P577 | publication date | 2009-10-22 | |
| P1433 | published in | Viruses | Q7935305 |
| P1476 | title | HBV and HCV therapy | |
| P478 | volume | 1 |
| Q45351713 | Adjuvant interferon therapy after surgical treatment for hepatitis B/C virus-related hepatocellular carcinoma: A meta-analysis |
| Q26774198 | Hepatitis B virus therapy: What's the future holding for us? |
| Q33753991 | Understanding the Complex Patterns Observed during Hepatitis B Virus Therapy. |
Search more.